Hypoglycemia Prevention in High-Risk Type 2 Diabetes Patients
Testing a New Population Management Model for Hypoglycemia Prevention in High-Risk KPNC Members
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Active KPNC members with valid MRNs at baseline (06/01/2023), 2. age \>=18 years, 3. in the KPNC diabetes registry, 4. likely type 2 diabetes (determined using a validated algorithm) 5. high risk for hypoglycemia, determined using the hypoglycemia risk stratification tool developed by the investigator team Exclusion Criteria: 1. Dementia or impaired cognition, 2. psychosis or schizophrenia diagnosis, 3. end-stage renal disease, 4. "no contact" preferences on file, 5. no primary care physician or home facility, 6. receiving care at skill nursing facilities, 7. deceased, 8. enrolled in concurrent pharmacy deprescribing pilots 9. Pregnant patients Aim 4: In addition to criteria above, participants will only include patients with type 2 diabetes (T2D) who use a CGM device, have authorized sharing of their CGM data with their healthcare provider and have evidence of "excess hypoglycemia" (\>=4% TBR on continuous glucose monitor readouts).
About the study
Severe low blood sugar (hypoglycemia) is a serious problem for people with diabetes. It can lead to dangerous falls, heart problems, memory issues, and even death. However, many healthcare providers don't recognize or manage this problem well. The investigators believe that creating a clear set of guidelines for preventing hypoglycemia, along with having a clinical pharmacist actively help high-risk patients, can make diabetes treatment safer.
In this study, the investigators developed a simple, evidence-based guide called "Hypoglycemia on a Page" (HOAP) to prevent low blood sugars. The investigators then tested it by comparing two groups of patients with type 2 diabetes who are at high risk for hypoglycemia. One group received active support from a clinical pharmacist using the HOAP guidelines, while the other group received standard care.
The main goal of this study is to see if the pharmacist's support leads to safer diabetes treatment. The investigators will also look at other factors, such as whether patients are prescribed glucagon (a medicine for severe low blood sugar), if they use continuous glucose monitoring, and whether they have worse blood sugar control or end up in the hospital for hypoglycemia. This trial aims to improve patient safety, health outcomes, and possibly lower healthcare costs.
What is being tested
- Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia) (behavioral)
- Usual care, after system-side dissemination of HOAP (behavioral)
Sponsor: Kaiser Permanente · Participants: 250 · Started: Jul 20, 2023
Contact the study team
- Lisa K Gilliam, MD, PhD · Phone: 650-676-7584
- Andrew J Karter, PhD · Phone: 206-817-5391
Official record on ClinicalTrials.gov — NCT06746714
Locations in the U.S.
| California | Kaiser Permanente Department of Research, Pleasanton |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.